Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKesson
Merck
Boehringer Ingelheim
McKinsey

Last Updated: February 1, 2023

Patent: 10,058,610


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 10,058,610
Title:Methods for treating cancer by administering humanized pan-HER antibody compositions
Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
Inventor(s): Lantto; Johan (Lund, SE), Andersen; Kim Vilbour (Bronshoj, DK), Andersen; Peter Sejer (Vanlose, DK), Strandh; Magnus (Malmo, SE), Koefoed; Klaus (Kobenhavn S, DK), Nielsen; Lars Sogaard (Niva, DK), Pedersen; Mikkel Wandahl (Alleroed, DK), Jacobsen; Helle (Virum, DK), Kragh; Michael (Copenhagen, DK), Kjaer; Ida (Copenhagen, DK), Poulsen; Thomas Tuxen (Dyssegaard, DK)
Assignee: Symphogen A/S (Ballerup, DK)
Application Number:15/350,801
Patent Claims:see list of patent claims

Details for Patent 10,058,610

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 See Plans and Pricing 2032-05-02
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 See Plans and Pricing 2032-05-02
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 See Plans and Pricing 2032-05-02
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 See Plans and Pricing 2032-05-02
Genentech, Inc. PERJETA pertuzumab Injection 125409 06/08/2012 See Plans and Pricing 2032-05-02
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 See Plans and Pricing 2032-05-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Boehringer Ingelheim
McKinsey
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.